

WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

Riamet Baby¹

Artemether/Lumefantrine 2.5 mg/30 mg dispersible tablets

Riamet Baby was submitted in 2026 by Novartis Pharma AG to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the treatment of malaria on 23 April 2026.

Information on the site(s) involved in the manufacture of the product and the API(s) is available at the products listing information: <https://extranet.who.int/prequal/medicines/ma217>

The “Procedure for prequalification of pharmaceutical products²” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQT/MED), is based on the approval by the “Swiss Agency for Therapeutic Products” (Swissmedic, <https://www.swissmedic.ch/swissmedic/de/home.html>) in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”³.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant⁴.

Based on the submitted stability data WHO PQT/MED considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

¹ Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

² https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2

³ https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aac767d_2

⁴ https://extranet.who.int/prequal/sites/default/files/document_files/48%20Stability%20data%20SRA%20FPPs_March_2016_newtempl.pdf

- Do not store above 30°C. Store in the original package and protect from heat and moisture. Avoid excursions above 30°C.
- The shelf-life at this storage condition is 24 months

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval.

<https://www.swissmedic.ch/swissmedic/en/home/services/medicinal-product-information.html>,
<https://www.swissmedicinfo-pro.ch/?Lang=EN>

For details on the uses of this product, for relevant efficacy and safety information see the summary of product characteristics and the patient information leaflet.

The English language version of the patient information leaflet, the summary of product characteristics, as certified to be "Swissmedic" approved texts, and the labelling are included in this WHOPAR.

This WHOPAR for Riamet Baby is comprised of parts 2, 3, 4, 5 and 7.

Riamet Baby contains artemether and lumefantrine. Its WHO recommended use is for treatment of malaria.

Summary of Prequalification Status for Riamet Baby

Initial acceptance	Date	Outcome
Status on PQ list	23 April 2026	listed
Quality	April 2026	MR
PQ: prequalification MR: meets requirements		

The table represents the status of relevant completed activities only.